Tharimmune (NASDAQ:THAR) Trading Down 6.3% – Time to Sell?

Tharimmune, Inc. (NASDAQ:THAR)’s share price dropped 6.3% during mid-day trading on Friday . The stock traded as low as $1.33 and last traded at $1.34. Approximately 29,721 shares were traded during trading, a decline of 92% from the average daily volume of 371,434 shares. The stock had previously closed at $1.43.

Tharimmune Stock Performance

The company has a market capitalization of $3.56 million, a P/E ratio of -0.17 and a beta of 1.04. The firm’s fifty day moving average is $1.40 and its 200-day moving average is $1.65.

Tharimmune (NASDAQ:THAR) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.15).

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned about 1.11% of Tharimmune at the end of the most recent reporting period. 1.16% of the stock is owned by institutional investors and hedge funds.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).